Last synced from Twitter 10m ago
Minority Women with Breast Cancer Show More Variants of Uncertain Significance
Given the uncertainty about the clinical implications of pathogenic or likely pathogenic variants in moderate penetrance genes and variants of uncertain significance, the findings may underscore the need for targeted genetic counseling education,...
MET Alterations are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer
Background: Most ALK -positive lung cancers will develop ALK-independent resistance after treatment with ALK inhibitors. MET amplification has been described in patients progressing on ALK inhibitors, but frequency of this event has not been...
Top Infectious Disease News of the Week - February 16, 2020
Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.
ASCO LDP: Medical Professionalism
Take this survey powered by surveymonkey.com. Create your own surveys for free.
Strategy execution habits of thriving practices
“Winning” practices follow five habits that contradict conventional wisdom to out-execute and out-compete their rivals.
How much space do you really need?
You may need to expand your practice, but if you use space wisely, you may need less than you think.
2020 Hospital of the Year—Jumping in, learning curve: First time’s the charm
Two young doctors dove right into practice ownership and building a facility all at once and got the practice of their dreams, earning them top honors in the under-8,000-square-feet category of the dvm360 Hospital Design Competition.
Hats Off to Hand Hygiene Ambassadors!
Sustainability of high hand hygiene rates is extremely challenging and continuously requires resources and substantial effort.
Rimegepant FDA-Approved for Acute Migraine Treatment
Rimegepant, the only orally disintegrating anti-CGRP tablet, marketed as Nurtec ODT, will be available in a 75-mg dose.
FDA Approves sNDA for Neratinib in Combination with Capecitabine for HER2+ Breast Cancer
The FDA approved a supplemental new drug application for neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received at least 2 prior anti-HER2-based...
Biliary Cancer: Current Multimodality Treatment and Future Directions
Clinicians discuss appropriate evaluation and choice of management strategies for cholangiocarcinoma.
Eileen M. O’Reilly, MD, on the Challenges of Treating Patients with Pancreatic Cancer
The medical oncologist from Memorial Sloan Kettering Cancer Center discussed challenges in treating patients with pancreatic center, and also the challenge of obtaining effective drugs in the clinical setting.
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges
The therapeutic armamentarium of acute myeloid leukemia (AML) has rapidly expanded in the past few years, driven largely by translational research into its genomic landscape and an improved understanding of mechanisms of resistance to conventional...
Dr. Gupta on BLASST-1 Results in Muscle-Invasive Bladder Cancer
Shilpa Gupta, MD, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic, discusses the results of the phase II BLASST-1 trial, which is evaluating nivolumab, gemcitabine, and cisplatin in patients with muscle-invasive...
Updated NCCN Guidelines on RNA Sequencing
NCCN Stresses the Importance of RNA Sequencing in Updated NSCLC Guidelines
Translocations and gene fusions represent approximately 20% of cancer mortality globally, however the detection and targeting of these events demonstrates a revolution in...